Sartorius (SRT3) AI Stock Analysis

• Market Cap: €12.84B
• Dividend Yield: 0.36%
• Average Volume (3M): 99.88K
• Price to Earnings (P/E): 149.0
• Beta (1Y): 1.81
• Revenue Growth: 3.99%
• EPS Growth: -36.36%
• Country: DE
• Employees: 13,573
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.22
• Shares Outstanding: 37,440,000
• 10 Day Avg. Volume: 138,811
• 30 Day Avg. Volume: 99,879
• PEG Ratio: 18.37
• Price to Book (P/B): 5.87
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 20.63
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €256.17
• Price Target Upside: 24.29% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 13

• Rating: 60 Neutral
• Price Target: €236.00 ▲(14.51%Upside)

Sartorius's overall stock score is primarily influenced by stable financial performance, with strong cash flow generation being a key strength. However, high leverage and declining profitability pose risks. The technical analysis shows mixed signals, with a slight bearish trend. The stock is considerably overvalued, as indicated by a high P/E ratio and a low dividend yield, which weighs down the overall score.

Positive Factors

Earnings

Sartorius AG delivered a 7% beat on EBITDA compared to consensus, which is considered a positive result.

Financial Performance

The guidance for EBITDA was raised to 30% at the high point, indicating strong performance expectations.

Growth Opportunity

The price target has an upside potential of 46.8%, suggesting a strong growth opportunity for investors.

Negative Factors

Bioprocessing Recovery

Bioprocessing recovery still below trend, implying that this is largely consumables driven.

EBITDA Performance

EBITDA was down 12%, in line with consensus, reflecting the volume and product mix effects.

Product Segment Performance

Lab products and services showed weakness with a decline in revenue and missed EBITDA estimates, highlighting concerns in equipment purchasing.

Sartorius Business Overview & Revenue Model

Company Description

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.

How the Company Makes Money

Sartorius generates revenue primarily through the sale of its bioprocess solutions and laboratory products. The Bioprocess Solutions segment accounts for the majority of its revenue, providing integrated solutions that streamline the development and manufacture of biopharmaceuticals. This includes the sale of proprietary technologies and consumables, such as filtration and purification systems, cell culture media, and single-use systems, which are critical for the production of biologics. The Lab Products & Services segment complements this by offering laboratory instruments, consumables, and services for research and quality assurance. Sartorius also leverages strategic partnerships and collaborations with biopharmaceutical companies to enhance its product offerings and expand its market reach, contributing to its financial performance.

Sartorius Financial Statement Overview

Summary

Sartorius demonstrates stable cash flow and asset management, with strong cash generation capabilities. However, profitability has been pressured in recent periods, with declining margins and revenue growth. Increasing leverage could pose future risks if not managed carefully. The company exhibits a balanced overall financial position, though attention to profitability and debt levels is necessary.

Income Statement

Sartorius shows a stable gross profit margin of around 45% to 50% over the periods, indicating efficient cost management. The net profit margin in the TTM stands at 3.63%, a drop from previous years, primarily due to decreased EBIT and net income. Revenue growth has been inconsistent, with a decline in 2025 TTM compared to the previous year. The EBIT and EBITDA margins have also contracted, pointing to reduced operational efficiency.

Balance Sheet

The company's debt-to-equity ratio increased slightly, reflecting higher leverage, which may pose financial risks. However, the equity ratio remains stable, suggesting a balanced capital structure. Return on equity has decreased to 4.62% in the TTM, indicating lower profitability for shareholders. While the company maintains solid asset management, rising liabilities could be a concern.

Cash Flow

Sartorius's operating cash flow has improved in the TTM, suggesting strong cash-generating ability. Free cash flow growth is robust, rising by approximately 21% compared to the previous period, indicating good cash management. The operating cash flow to net income ratio is elevated, reflecting strong cash conversion despite lower net income. Overall, cash flow management appears solid, supporting financial stability.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
3.44B	3.38B	3.40B	4.17B	3.45B	2.34B
	Gross Profit
1.56B	1.52B	1.57B	2.20B	1.84B	1.21B
	EBIT
353.70M	437.20M	543.20M	1.14B	735.80M	523.47M
	EBITDA
831.60M	786.80M	873.10M	1.54B	945.12M	662.13M
	Net Income Common Stockholders
125.10M	84.00M	205.20M	913.10M	426.98M	321.47M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.10B	828.70M	394.20M	196.80M	360.99M	217.65M
	Total Assets
10.63B	10.10B	9.76B	6.98B	5.70B	4.70B
	Total Debt
5.20B	4.56B	5.31B	2.54B	2.08B	2.09B
	Net Debt
4.10B	3.75B	4.93B	2.38B	1.73B	1.88B
	Total Liabilities
6.87B	6.21B	7.00B	4.32B	3.98B	3.30B
	Stockholders Equity
2.67B	2.76B	2.07B	1.99B	1.26B	1.05B
Cash Flow		Free Cash Flow
687.30M	566.30M	293.90M	211.60M	458.65M	271.27M
	Operating Cash Flow
1.04B	976.20M	853.60M	734.20M	865.81M	511.52M
	Investing Cash Flow
-374.40M	-425.80M	-2.82B	-1.13B	-569.61M	-1.27B
	Financing Cash Flow
-944.30M	-128.30M	2.17B	209.90M	-165.18M	907.47M

Sartorius Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 206.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:SRT3, the sentiment is Negative. The current price of 206.1 is below the 20-day moving average (MA) of 221.45, below the 50-day MA of 216.10, and below the 200-day MA of 231.21, indicating a bearish trend. The MACD of -4.51 indicates Positive momentum. The RSI at 35.49 is Neutral, neither overbought nor oversold. The STOCH value of 19.53 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:SRT3.

Sartorius Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SRT3	60 Neutral	€12.84B	148.99	3.55%	0.36%	3.99%	-36.36%
Sector *	54 Neutral	$5.28B	3.29	-45.38%	2.80%	16.77%	-0.08%
0DHC		€4.88B	30.83	7.48%	1.04%	―	―
0H9X		€14.62B	23.90	4.37%	2.89%	―	―
0OO9		€24.45B	59.05	6.28%	2.28%	―	―
0O14		€50.56B	17.80	9.74%	1.89%	―	―
SEMHF		$58.84B	25.90	11.14%	2.01%	―	―